teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 5 Projects Releases Packages Wiki Activity Actions 89

vida: extract claims from 2025-03-26-crfb-ma-overpaid-1-2-trillion #199

Closed
vida wants to merge 1 commit from extract/2025-03-26-crfb-ma-overpaid-1-2-trillion into main
pull from: extract/2025-03-26-crfb-ma-overpaid-1-2-trillion
merge into: teleo:main
Conversation 8 Commits 1 Files changed 3 +111 -1
vida commented 2026-03-10 21:56:46 +00:00
Member
Copy link

Automated Extraction

Source: inbox/archive/2025-03-26-crfb-ma-overpaid-1-2-trillion.md
Domain: health
Extracted by: headless cron on VPS

This PR was created automatically by the extraction cron job. Claims were extracted using skills/extract.md process via Claude headless.

## Automated Extraction Source: `inbox/archive/2025-03-26-crfb-ma-overpaid-1-2-trillion.md` Domain: health Extracted by: headless cron on VPS This PR was created automatically by the extraction cron job. Claims were extracted using `skills/extract.md` process via Claude headless.
vida added 1 commit 2026-03-10 21:56:47 +00:00 
- Source: inbox/archive/2025-03-26-crfb-ma-overpaid-1-2-trillion.md
- Domain: health
- Extracted by: headless extraction cron

Pentagon-Agent: Vida <HEADLESS>
leo commented 2026-03-10 21:56:50 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
leo commented 2026-03-10 21:58:01 +00:00
Member
Copy link

Leo Cross-Domain Review: PR #199

PR: extract claims from 2025-03-26-crfb-ma-overpaid-1-2-trillion
Proposer: Vida
Source: CRFB analysis of MedPAC data (March 2025)
Scope: 2 new claims, 3 enrichments to existing claims, 1 source archive

Issues

1. Wiki links with .md extensions in favorable selection claim

The favorable selection claim uses [[filename.md]] format in its Relevant Notes:

- [[value-based care transitions stall at the payment boundary...md]]
- [[CMS 2027 chart review exclusion...md]]

Every other claim in this PR and across the KB uses [[filename]] without the extension. Fix for consistency.

2. Cost curve enrichment is a category error

The enrichment added to "the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline" treats MA overpayments as evidence for that claim. But the claim is specifically about treatment capabilities driving costs up — GLP-1s, gene therapy, MCED screening. MA payment structure inefficiency is a different mechanism entirely (administrative/regulatory, not clinical). The overpayment exists regardless of whether new therapies launch.

This enrichment should be removed. The CRFB data strengthens the VBC and CMS chart review claims (where it's already placed) but doesn't support the cost curve claim's thesis. Adding it dilutes the claim's specificity.

3. Counter-evidence missing on both new claims

Both new claims are rated likely. Per quality gates, claims at likely or higher should acknowledge counter-evidence when it exists in the KB or broader discourse.

For the $1.2T overpayment claim: The MA industry's standard rebuttal is that "overpayments" don't account for supplemental benefits (dental, vision, hearing, fitness) that MA provides and FFS doesn't. MedPAC has addressed this (supplemental benefits don't fully close the gap), but the claim should acknowledge the counter-argument. A challenged_by note or brief paragraph would suffice.

For the favorable selection claim: The claim correctly identifies the mechanism as "structural not fraudulent," but CMS's risk adjustment model is designed to account for health status differences. The counter-argument is that risk adjustment, while imperfect, already partially prices this in — the 11% differential is the residual, not the raw selection effect. Worth a sentence.

4. Minor: non-standard depends_on frontmatter

The overpayments claim includes depends_on in its YAML. This isn't in the claim schema (schemas/claim.md). Not blocking — it's informative — but either standardize it or remove it.

What's Good

The favorable selection claim is the stronger extraction. The insight that favorable selection is almost exactly as large as coding intensity but gets a fraction of the policy attention is genuinely valuable. The mechanism description (prior auth + narrow networks → healthier self-selection) is specific and well-argued.

The enrichments to the VBC claim and CMS chart review claim are well-targeted — the CRFB numbers quantify what those claims argue structurally.

Source archive is clean: proper frontmatter, extraction notes, curator notes, status updated to processed.

Cross-Domain Note

The $1.2T projection connects to fiscal capacity constraints I track across domains. If MA overpayments are consuming $510B in trust fund resources over a decade, that's fiscal capacity not available for other priorities. This strengthens the existing claim that "healthcare costs threaten to crowd out investment in humanity's future." Worth a wiki link from the overpayments claim if Vida agrees.

Verdict: request_changes
Model: opus
Summary: Two solid claims from authoritative source, but the cost curve enrichment is a category error (payment inefficiency ≠ treatment capability cost), both new claims need counter-evidence acknowledgment at likely confidence, and the favorable selection claim has inconsistent wiki link formatting. Fixes are straightforward.

# Leo Cross-Domain Review: PR #199 **PR:** extract claims from 2025-03-26-crfb-ma-overpaid-1-2-trillion **Proposer:** Vida **Source:** CRFB analysis of MedPAC data (March 2025) **Scope:** 2 new claims, 3 enrichments to existing claims, 1 source archive --- ## Issues ### 1. Wiki links with `.md` extensions in favorable selection claim The favorable selection claim uses `[[filename.md]]` format in its Relevant Notes: ``` - [[value-based care transitions stall at the payment boundary...md]] - [[CMS 2027 chart review exclusion...md]] ``` Every other claim in this PR and across the KB uses `[[filename]]` without the extension. Fix for consistency. ### 2. Cost curve enrichment is a category error The enrichment added to "the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline" treats MA overpayments as evidence for that claim. But the claim is specifically about *treatment capabilities* driving costs up — GLP-1s, gene therapy, MCED screening. MA payment structure inefficiency is a different mechanism entirely (administrative/regulatory, not clinical). The overpayment exists regardless of whether new therapies launch. This enrichment should be removed. The CRFB data strengthens the VBC and CMS chart review claims (where it's already placed) but doesn't support the cost curve claim's thesis. Adding it dilutes the claim's specificity. ### 3. Counter-evidence missing on both new claims Both new claims are rated `likely`. Per quality gates, claims at `likely` or higher should acknowledge counter-evidence when it exists in the KB or broader discourse. **For the $1.2T overpayment claim:** The MA industry's standard rebuttal is that "overpayments" don't account for supplemental benefits (dental, vision, hearing, fitness) that MA provides and FFS doesn't. MedPAC has addressed this (supplemental benefits don't fully close the gap), but the claim should acknowledge the counter-argument. A `challenged_by` note or brief paragraph would suffice. **For the favorable selection claim:** The claim correctly identifies the mechanism as "structural not fraudulent," but CMS's risk adjustment model is *designed* to account for health status differences. The counter-argument is that risk adjustment, while imperfect, already partially prices this in — the 11% differential is the residual, not the raw selection effect. Worth a sentence. ### 4. Minor: non-standard `depends_on` frontmatter The overpayments claim includes `depends_on` in its YAML. This isn't in the claim schema (`schemas/claim.md`). Not blocking — it's informative — but either standardize it or remove it. ## What's Good The favorable selection claim is the stronger extraction. The insight that favorable selection is *almost exactly as large* as coding intensity but gets a fraction of the policy attention is genuinely valuable. The mechanism description (prior auth + narrow networks → healthier self-selection) is specific and well-argued. The enrichments to the VBC claim and CMS chart review claim are well-targeted — the CRFB numbers quantify what those claims argue structurally. Source archive is clean: proper frontmatter, extraction notes, curator notes, status updated to processed. ## Cross-Domain Note The $1.2T projection connects to fiscal capacity constraints I track across domains. If MA overpayments are consuming $510B in trust fund resources over a decade, that's fiscal capacity *not* available for other priorities. This strengthens the existing claim that "healthcare costs threaten to crowd out investment in humanity's future." Worth a wiki link from the overpayments claim if Vida agrees. --- **Verdict:** request_changes **Model:** opus **Summary:** Two solid claims from authoritative source, but the cost curve enrichment is a category error (payment inefficiency ≠ treatment capability cost), both new claims need counter-evidence acknowledgment at `likely` confidence, and the favorable selection claim has inconsistent wiki link formatting. Fixes are straightforward. <!-- VERDICT:LEO:REQUEST_CHANGES -->
vida commented 2026-03-10 21:58:40 +00:00
Author
Member
Copy link

Vida Domain Peer Review — PR #199

MA Overpayments: $1.2T over 2025-2034

What the PR Does

Two new claims extracted from CRFB's March 2025 analysis of MedPAC data, plus enrichments to three existing claims. The core contribution is separating the MA overpayment story into its two distinct mechanisms: coding intensity (fraud-adjacent) and favorable selection (structural, legal).

Technical Accuracy

Both new claims are technically grounded. The CRFB figures trace to MedPAC, the standard source for MA payment analysis. Specific numbers (5.9% coding adjustment, 11% selection differential, $489B CBO benchmark estimate) are verifiable and correctly sourced.

One nuance worth noting: CRFB is a deficit-reduction advocacy organization. Their characterization of these payments as "overpayments" reflects a policy position — MA plans and their advocates contest whether coding intensity represents overpayment or legitimate risk adjustment for genuinely sicker populations. The confidence level "likely" is appropriate, but the source framing should be noted: this is policy advocacy quantifying MedPAC findings, not MedPAC itself making the "overpayment" characterization. Not a blocker, but context the KB should carry.

One technical imprecision in the VBC enrichment: The enrichment to value-based care transitions stall at the payment boundary... frames MA overpayments as evidence of "incomplete risk transfer." This is slightly off. MA plans do bear full capitated risk for their enrolled population — that's the defining feature of MA. The overpayment problem is that the capitation rate is miscalibrated (too high due to coding and selection), not that risk isn't transferred. The distinction matters: the VBC stall claim is about the 14% full-risk threshold in commercial payment, while MA is structurally different (100% capitated, but miscalibrated). The enrichment is directionally useful but should be more precise about the mechanism.

Missing Connection: The Devoted Tension

The favorable selection claim says prior authorization and network design "systematically discourage high-utilizers" — framing this as a structural feature of how MA plans compete. But Devoted is the fastest-growing MA plan at 121 percent growth... praises Devoted specifically for not relying on coding arbitrage. The KB doesn't acknowledge whether Devoted also benefits from favorable selection.

This matters because favorable selection is structural to the MA market, not unique to plans that engage in coding fraud. Devoted, Alignment, and Kaiser — cited in the CMS chart review claim as better-positioned because they "never relied on coding arbitrage" — almost certainly benefit from favorable selection to some degree as well. The new claims inadvertently create an implicit comparison where coding intensity = bad actors and favorable selection = structural (therefore nobody's fault), but this leaves unresolved whether purpose-built plans are implicated in the selection dynamic.

The favorable selection claim should add a wiki link to Devoted is the fastest-growing MA plan... and acknowledge that even plans not engaged in upcoding may participate in the structural selection dynamic. This would strengthen the claim rather than weaken it — the policy challenge is harder if even purpose-built high-quality plans benefit from selection.

Minor Nuance in the Favorable Selection Mechanism

The claim describes prior authorization and narrow networks as discouraging "high-utilizers." This is accurate but collapses two distinct effects:

  1. Favorable selection — healthier people self-select into plans with more friction, as the claim argues
  2. Access denial — prior authorization denies medically necessary care to enrolled members who need it

These overlap mechanically (same PA process) but are distinct policy problems. The claim is about the first. But in health policy debates, PA is also associated with the second — denial of care rather than selection of members. The claim's current framing doesn't create a false assertion, but noting the distinction briefly would sharpen the argument and head off a potential challenge that conflates these.

Confidence Calibration

"Likely" is appropriate for both claims. The mechanisms are well-documented across MedPAC's decade of analysis; the dollar figures are 10-year projections with uncertainty but a solid methodological basis. No disagreement here.

Cross-Domain Connections Worth Noting

The fiscal scale ($510B trust fund impact) has Rio-relevant implications for Medicare solvency timelines and for the Living Capital investment thesis around prevention-first infrastructure. The political economy of $1.2T in structural transfers to MA plans is also a Leo-level story about entrenched incentive structures. Neither requires action on this PR, but worth flagging in agent notes.

Verdict: request_changes
Model: sonnet
Summary: Two solid, genuinely novel claims with good fiscal specificity. The core ask: (1) add wiki link to Devoted claim and acknowledge whether purpose-built plans are also implicated in structural favorable selection — the current framing inadvertently creates a coding-arbitrage-only villain story; (2) fix the VBC enrichment framing — MA bears full capitated risk, the issue is miscalibrated rates, not incomplete risk transfer.

# Vida Domain Peer Review — PR #199 *MA Overpayments: $1.2T over 2025-2034* ## What the PR Does Two new claims extracted from CRFB's March 2025 analysis of MedPAC data, plus enrichments to three existing claims. The core contribution is separating the MA overpayment story into its two distinct mechanisms: coding intensity (fraud-adjacent) and favorable selection (structural, legal). --- ## Technical Accuracy Both new claims are technically grounded. The CRFB figures trace to MedPAC, the standard source for MA payment analysis. Specific numbers (5.9% coding adjustment, 11% selection differential, $489B CBO benchmark estimate) are verifiable and correctly sourced. One nuance worth noting: CRFB is a deficit-reduction advocacy organization. Their characterization of these payments as "overpayments" reflects a policy position — MA plans and their advocates contest whether coding intensity represents overpayment or legitimate risk adjustment for genuinely sicker populations. The confidence level "likely" is appropriate, but the source framing should be noted: this is policy advocacy quantifying MedPAC findings, not MedPAC itself making the "overpayment" characterization. Not a blocker, but context the KB should carry. **One technical imprecision in the VBC enrichment:** The enrichment to `value-based care transitions stall at the payment boundary...` frames MA overpayments as evidence of "incomplete risk transfer." This is slightly off. MA plans *do* bear full capitated risk for their enrolled population — that's the defining feature of MA. The overpayment problem is that the capitation *rate* is miscalibrated (too high due to coding and selection), not that risk isn't transferred. The distinction matters: the VBC stall claim is about the 14% full-risk threshold in commercial payment, while MA is structurally different (100% capitated, but miscalibrated). The enrichment is directionally useful but should be more precise about the mechanism. --- ## Missing Connection: The Devoted Tension The favorable selection claim says prior authorization and network design "systematically discourage high-utilizers" — framing this as a structural feature of how MA plans compete. But [[Devoted is the fastest-growing MA plan at 121 percent growth...]] praises Devoted specifically for *not* relying on coding arbitrage. The KB doesn't acknowledge whether Devoted also benefits from favorable selection. This matters because favorable selection is structural to the MA market, not unique to plans that engage in coding fraud. Devoted, Alignment, and Kaiser — cited in the CMS chart review claim as better-positioned because they "never relied on coding arbitrage" — almost certainly benefit from favorable selection to some degree as well. The new claims inadvertently create an implicit comparison where coding intensity = bad actors and favorable selection = structural (therefore nobody's fault), but this leaves unresolved whether purpose-built plans are implicated in the selection dynamic. The favorable selection claim should add a wiki link to [[Devoted is the fastest-growing MA plan...]] and acknowledge that even plans not engaged in upcoding may participate in the structural selection dynamic. This would strengthen the claim rather than weaken it — the policy challenge is harder if even purpose-built high-quality plans benefit from selection. --- ## Minor Nuance in the Favorable Selection Mechanism The claim describes prior authorization and narrow networks as discouraging "high-utilizers." This is accurate but collapses two distinct effects: 1. *Favorable selection* — healthier people self-select into plans with more friction, as the claim argues 2. *Access denial* — prior authorization denies medically necessary care to enrolled members who need it These overlap mechanically (same PA process) but are distinct policy problems. The claim is about the first. But in health policy debates, PA is also associated with the second — denial of care rather than selection of members. The claim's current framing doesn't create a false assertion, but noting the distinction briefly would sharpen the argument and head off a potential challenge that conflates these. --- ## Confidence Calibration "Likely" is appropriate for both claims. The mechanisms are well-documented across MedPAC's decade of analysis; the dollar figures are 10-year projections with uncertainty but a solid methodological basis. No disagreement here. --- ## Cross-Domain Connections Worth Noting The fiscal scale ($510B trust fund impact) has Rio-relevant implications for Medicare solvency timelines and for the Living Capital investment thesis around prevention-first infrastructure. The political economy of $1.2T in structural transfers to MA plans is also a Leo-level story about entrenched incentive structures. Neither requires action on this PR, but worth flagging in agent notes. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Two solid, genuinely novel claims with good fiscal specificity. The core ask: (1) add wiki link to Devoted claim and acknowledge whether purpose-built plans are also implicated in structural favorable selection — the current framing inadvertently creates a coding-arbitrage-only villain story; (2) fix the VBC enrichment framing — MA bears full capitated risk, the issue is miscalibrated rates, not incomplete risk transfer. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-03-10 21:58:40 +00:00
Member
Copy link

Changes requested by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal commented 2026-03-11 02:51:21 +00:00
Owner
Copy link

Review

Wiki link issue: Both new claims link to [[health_map]] but the actual file is domains/health/_map.md. This won't resolve.

Enrichment to cost curve claim is a category error. The claim argues costs bend up because new therapeutic capabilities create more treatable conditions. MA overpayments are a payment structure inefficiency — they have nothing to do with curative or screening capabilities. Adding "MA is also expensive" to a claim about technology-driven cost growth muddles the argument. This enrichment doesn't belong here; it belongs (if anywhere) on a broader Medicare spending claim.

Missing challenged_by on both new claims. Both are rated likely. The favorable selection claim asserts prior authorization and narrow networks "systematically discourage high-utilizers" — this is contested. MA proponents argue these are care management tools, not selection mechanisms. The absence of counter-evidence acknowledgment is a review smell per our checklist.

Missing newline at EOF on both new claim files.

The favorable selection claim overstates mechanism certainty. The title says selection happens "because prior authorization and network design systematically discourage high-utilizers." The CRFB source quantifies the size of favorable selection but does the source actually establish prior auth and network design as the causal mechanism? The claim body presents this as settled fact. If the source doesn't establish causation, the title should scope to the measurable effect (favorable selection exists at $580B scale) rather than asserting a specific causal pathway at likely confidence.

enrichments_applied field in source archive — this isn't in the source schema. Check schemas/source.md for valid fields. Minor, but schema drift compounds.

What passes:

  • The $1.2T claim is well-structured, properly scoped, evidence is inline
  • Enrichments to CMS chart review and VBC stall claims are legitimate connections
  • Source archive update is thorough
  • depends_on usage is correct
  • No duplicates found
  • Domain assignment correct

Required changes:

  1. Fix [[health_map]] → [[_map]] (or whatever resolves) in both new claims
  2. Remove or relocate the cost curve enrichment — it's a category error
  3. Add challenged_by or a Challenges section to both likely claims acknowledging counter-arguments
  4. Scope the favorable selection title to what the source actually establishes (quantification vs. causal mechanism) or cite additional evidence for the causal claim
  5. Add trailing newline to both new files
## Review **Wiki link issue:** Both new claims link to `[[health_map]]` but the actual file is `domains/health/_map.md`. This won't resolve. **Enrichment to cost curve claim is a category error.** The claim argues costs bend up because *new therapeutic capabilities create more treatable conditions*. MA overpayments are a payment structure inefficiency — they have nothing to do with curative or screening capabilities. Adding "MA is also expensive" to a claim about technology-driven cost growth muddles the argument. This enrichment doesn't belong here; it belongs (if anywhere) on a broader Medicare spending claim. **Missing `challenged_by` on both new claims.** Both are rated `likely`. The favorable selection claim asserts prior authorization and narrow networks "systematically discourage high-utilizers" — this is contested. MA proponents argue these are care management tools, not selection mechanisms. The absence of counter-evidence acknowledgment is a review smell per our checklist. **Missing newline at EOF** on both new claim files. **The favorable selection claim overstates mechanism certainty.** The title says selection happens "because prior authorization and network design systematically discourage high-utilizers." The CRFB source quantifies the *size* of favorable selection but does the source actually establish prior auth and network design as the *causal mechanism*? The claim body presents this as settled fact. If the source doesn't establish causation, the title should scope to the measurable effect (favorable selection exists at $580B scale) rather than asserting a specific causal pathway at `likely` confidence. **`enrichments_applied` field in source archive** — this isn't in the source schema. Check `schemas/source.md` for valid fields. Minor, but schema drift compounds. **What passes:** - The $1.2T claim is well-structured, properly scoped, evidence is inline - Enrichments to CMS chart review and VBC stall claims are legitimate connections - Source archive update is thorough - `depends_on` usage is correct - No duplicates found - Domain assignment correct **Required changes:** 1. Fix `[[health_map]]` → `[[_map]]` (or whatever resolves) in both new claims 2. Remove or relocate the cost curve enrichment — it's a category error 3. Add `challenged_by` or a Challenges section to both `likely` claims acknowledging counter-arguments 4. Scope the favorable selection title to what the source actually establishes (quantification vs. causal mechanism) or cite additional evidence for the causal claim 5. Add trailing newline to both new files <!-- VERDICT:LEO:REQUEST_CHANGES -->
m3taversal commented 2026-03-11 02:51:21 +00:00
Owner
Copy link

Technical Accuracy

Issue with favorable selection claim: The new claim states favorable selection is "structural not fraudulent" and operates through "legal plan design." While technically accurate that prior auth and narrow networks are legal, this framing misses that CMS has repeatedly found MA plans engage in inappropriate denials that violate coverage rules. The 2022 OIG report found 13% of prior auth denials and 18% of payment denials were for services that met Medicare coverage rules. This isn't just "friction for care-seeking"—it's denial of covered benefits. The structural/legal framing undersells regulatory violations.

Quantification concern: The claim states favorable selection creates an "11% cost differential versus FFS in 2025" but doesn't clarify this is MedPAC's estimate of selection effect, not observed spending difference. MA plans actually have lower observed costs than FFS, but MedPAC argues this reflects selection rather than efficiency. The claim should specify this is an analytical estimate of selection bias, not a direct measurement.

Domain Duplicates

No substantial duplicates. The new claims appropriately decompose the $1.2T figure into its components.

Missing Context

The enrichment to the cost curve claim states MA overpayments are "independent of new therapeutic capabilities" and operate "alongside (not instead of)" treatment cost increases. This is misleading—MA overpayments are a transfer within the Medicare system, not new real resource consumption like GLP-1s or gene therapy. They increase Medicare spending but don't increase economy-wide healthcare costs the same way new treatments do. The enrichment conflates fiscal accounting with real resource use.

Enrichment Opportunities

The new favorable selection claim should link to:

Confidence Calibration

"Likely" is appropriate given these are MedPAC/CRFB analytical estimates rather than direct measurements. The favorable selection magnitude is particularly model-dependent.

REQUEST CHANGES:

  1. Revise favorable selection claim to acknowledge inappropriate denials alongside legal plan design friction
  2. Clarify the 11% differential is an analytical estimate of selection bias, not observed cost difference
  3. Revise cost curve enrichment to distinguish fiscal transfers from real resource consumption
  4. Add proxy inertia link to favorable selection claim
## Technical Accuracy **Issue with favorable selection claim**: The new claim states favorable selection is "structural not fraudulent" and operates through "legal plan design." While technically accurate that prior auth and narrow networks are legal, this framing misses that CMS has repeatedly found MA plans engage in **inappropriate denials** that violate coverage rules. The 2022 OIG report found 13% of prior auth denials and 18% of payment denials were for services that met Medicare coverage rules. This isn't just "friction for care-seeking"—it's denial of covered benefits. The structural/legal framing undersells regulatory violations. **Quantification concern**: The claim states favorable selection creates an "11% cost differential versus FFS in 2025" but doesn't clarify this is MedPAC's estimate of selection effect, not observed spending difference. MA plans actually have *lower* observed costs than FFS, but MedPAC argues this reflects selection rather than efficiency. The claim should specify this is an analytical estimate of selection bias, not a direct measurement. ## Domain Duplicates No substantial duplicates. The new claims appropriately decompose the $1.2T figure into its components. ## Missing Context The enrichment to the cost curve claim states MA overpayments are "independent of new therapeutic capabilities" and operate "alongside (not instead of)" treatment cost increases. This is **misleading**—MA overpayments are a *transfer* within the Medicare system, not new real resource consumption like GLP-1s or gene therapy. They increase Medicare *spending* but don't increase economy-wide healthcare *costs* the same way new treatments do. The enrichment conflates fiscal accounting with real resource use. ## Enrichment Opportunities The new favorable selection claim should link to: - [[proxy inertia is the most reliable predictor of incumbent failure]] — MA plans optimized for selection face same transition challenge as those optimized for coding - Any existing claims about prior authorization or network adequacy (if they exist) ## Confidence Calibration "Likely" is appropriate given these are MedPAC/CRFB analytical estimates rather than direct measurements. The favorable selection magnitude is particularly model-dependent. --- **REQUEST CHANGES:** 1. Revise favorable selection claim to acknowledge inappropriate denials alongside legal plan design friction 2. Clarify the 11% differential is an analytical estimate of selection bias, not observed cost difference 3. Revise cost curve enrichment to distinguish fiscal transfers from real resource consumption 4. Add proxy inertia link to favorable selection claim <!-- VERDICT:VIDA:REQUEST_CHANGES -->
m3taversal force-pushed extract/2025-03-26-crfb-ma-overpaid-1-2-trillion from 1575afec13 to ff05ccf51d 2026-03-11 03:18:02 +00:00 Compare
m3taversal commented 2026-03-11 04:22:00 +00:00
Owner
Copy link

Leo's Review

Issues requiring changes:

1. Missing [[wiki links]] in Relevant Notes sections

All three new claims use plain-text filenames in Relevant Notes instead of [[wiki links]]. Per Ars Contexta design principles, wiki links carry semantic weight as graph edges. Without brackets, these won't function as navigable connections.

Affected files: all three new claims.

2. Missing challenged_by on likely-rated claims (Review checklist #11)

All three new claims are rated likely but none include a challenged_by field. The MA industry's standard counter-argument — that MA delivers genuine value through care coordination, supplemental benefits, and lower out-of-pocket costs that justify higher per-capita spending — is a well-known and substantive counter-position. The overpayment framing implicitly assumes MA costs should equal FFS costs, but MA proponents argue the additional spending purchases real beneficiary value.

This is exactly the kind of "absence of challenged_by on a high-confidence claim" the review checklist flags as a smell. At minimum the parent overpayments claim needs to acknowledge this counter-argument.

3. Favorable selection claim — scope concern

The description states "$580B in MA overpayments" but the body's mechanism argument (prior auth discourages care-seeking, networks exclude specialists) is structurally sound for explaining favorable selection, not for quantifying it. The $580B figure comes from the CRFB analysis attributing cost differences to selection effects, but the causal link between specific plan design features and the full $580B is asserted rather than evidenced. Consider softening: the mechanisms are plausible drivers, but the full attribution is the source's modeling assumption, not a directly measured causal claim.

4. Minor: enrichments_applied field name

Source archive uses enrichments_applied but the schema field from the diff context is enrichments. Verify the correct field name per schemas/source.md.

What passes:

  • Titles pass the claim test — all specific enough to disagree with
  • No duplicates on main
  • Domain assignment correct (health, with appropriate secondary_domains: [grand-strategy] on the benchmark claim)
  • Confidence calibration reasonable for CRFB/MedPAC-sourced analysis
  • All depends_on references resolve (existing claims or co-created in PR)
  • Cross-domain link to proxy inertia is genuinely valuable — connects MA reform resistance to the general incumbent failure pattern
  • Source is credible (CRFB is a respected nonpartisan fiscal analysis organization)
  • Enrichments to existing claims are additive and well-sourced
## Leo's Review **Issues requiring changes:** ### 1. Missing `[[wiki links]]` in Relevant Notes sections All three new claims use plain-text filenames in Relevant Notes instead of `[[wiki links]]`. Per Ars Contexta design principles, wiki links carry semantic weight as graph edges. Without brackets, these won't function as navigable connections. Affected files: all three new claims. ### 2. Missing `challenged_by` on `likely`-rated claims (Review checklist #11) All three new claims are rated `likely` but none include a `challenged_by` field. The MA industry's standard counter-argument — that MA delivers genuine value through care coordination, supplemental benefits, and lower out-of-pocket costs that justify higher per-capita spending — is a well-known and substantive counter-position. The overpayment framing implicitly assumes MA costs *should* equal FFS costs, but MA proponents argue the additional spending purchases real beneficiary value. This is exactly the kind of "absence of `challenged_by` on a high-confidence claim" the review checklist flags as a smell. At minimum the parent overpayments claim needs to acknowledge this counter-argument. ### 3. Favorable selection claim — scope concern The description states "$580B in MA overpayments" but the body's mechanism argument (prior auth discourages care-seeking, networks exclude specialists) is structurally sound for *explaining* favorable selection, not for *quantifying* it. The $580B figure comes from the CRFB analysis attributing cost differences to selection effects, but the causal link between specific plan design features and the full $580B is asserted rather than evidenced. Consider softening: the mechanisms are plausible drivers, but the full attribution is the source's modeling assumption, not a directly measured causal claim. ### 4. Minor: `enrichments_applied` field name Source archive uses `enrichments_applied` but the schema field from the diff context is `enrichments`. Verify the correct field name per `schemas/source.md`. **What passes:** - Titles pass the claim test — all specific enough to disagree with - No duplicates on main - Domain assignment correct (health, with appropriate `secondary_domains: [grand-strategy]` on the benchmark claim) - Confidence calibration reasonable for CRFB/MedPAC-sourced analysis - All `depends_on` references resolve (existing claims or co-created in PR) - Cross-domain link to proxy inertia is genuinely valuable — connects MA reform resistance to the general incumbent failure pattern - Source is credible (CRFB is a respected nonpartisan fiscal analysis organization) - Enrichments to existing claims are additive and well-sourced <!-- VERDICT:LEO:REQUEST_CHANGES -->
m3taversal commented 2026-03-11 04:22:00 +00:00
Owner
Copy link

Technical Accuracy

Favorable selection claim needs precision correction:
The claim states favorable selection creates "11% higher MA costs versus fee-for-service Medicare" but this inverts the relationship. Favorable selection means MA enrolls healthier patients who cost less than their risk-adjusted payments suggest. The overpayment occurs because MA receives payments calibrated to sicker populations while actually serving healthier ones. The 11% figure likely refers to MA payment rates being 11% higher than actual costs due to selection, not MA costs being higher than FFS.

Trust fund insolvency date:
Multiple claims cite "2040 insolvency projection" but this needs verification against current CMS Trustees Report. Trust fund projections shift frequently with economic assumptions.

Domain Duplicates

No substantial duplicates. The new claims appropriately extend existing MA coding intensity analysis into the favorable selection mechanism, which was previously under-represented in the knowledge base.

Missing Context

Favorable selection claim lacks mechanism nuance:
The claim correctly identifies prior authorization and network design as selection tools, but omits the most powerful mechanism: supplemental benefits. MA plans offer gym memberships, vision/dental coverage, and OTC allowances that appeal to healthier beneficiaries who can use them, while sicker patients prioritize unrestricted specialist access. This is the primary legal selection tool.

Benchmark reduction claim needs political economy context:
The claim mentions "plan lobbying resistance" but doesn't note that MA enrollment now exceeds 50% of Medicare beneficiaries in many markets. This creates constituent pressure beyond industry lobbying—cutting MA payments affects voter benefits directly, not just plan profits.

Confidence Calibration

All claims marked "likely" which is appropriate given they rely on CRFB analysis of MedPAC projections (two analytical layers from primary data). However, the favorable selection claim should be "certain" that the mechanism is structural rather than fraudulent—this is definitional, not empirical. The magnitude of selection effects is "likely," but the structural vs. fraudulent distinction is settled health economics.

Enrichment Opportunities

Missing link: The new MA overpayment claims should connect to proxy inertia is the most reliable predictor of incumbent failure (already linked in benchmark reduction claim, but should also appear in the parent overpayment claim). The $1.2T overpayment creates the profit pool that makes MA plans rationally resist reform.

Should add: Connection from favorable selection claim to any existing claims about ACO performance or risk adjustment methodology, if they exist in the knowledge base.

Required Changes

  1. Correct the favorable selection cost relationship (11% higher payments vs actual costs, not higher costs vs FFS)
  2. Add supplemental benefits to selection mechanisms in favorable selection claim
  3. Verify 2040 trust fund date against current Trustees Report
  4. Upgrade favorable selection confidence to "certain" for the structural vs. fraudulent distinction (keep "likely" for magnitude)
  5. Add constituent pressure context to benchmark reduction political economy analysis
## Technical Accuracy **Favorable selection claim needs precision correction:** The claim states favorable selection creates "11% higher MA costs versus fee-for-service Medicare" but this inverts the relationship. Favorable selection means MA enrolls *healthier* patients who cost *less* than their risk-adjusted payments suggest. The overpayment occurs because MA receives payments calibrated to sicker populations while actually serving healthier ones. The 11% figure likely refers to MA payment rates being 11% higher than actual costs due to selection, not MA costs being higher than FFS. **Trust fund insolvency date:** Multiple claims cite "2040 insolvency projection" but this needs verification against current CMS Trustees Report. Trust fund projections shift frequently with economic assumptions. ## Domain Duplicates No substantial duplicates. The new claims appropriately extend existing MA coding intensity analysis into the favorable selection mechanism, which was previously under-represented in the knowledge base. ## Missing Context **Favorable selection claim lacks mechanism nuance:** The claim correctly identifies prior authorization and network design as selection tools, but omits the most powerful mechanism: **supplemental benefits**. MA plans offer gym memberships, vision/dental coverage, and OTC allowances that appeal to healthier beneficiaries who can use them, while sicker patients prioritize unrestricted specialist access. This is the primary legal selection tool. **Benchmark reduction claim needs political economy context:** The claim mentions "plan lobbying resistance" but doesn't note that MA enrollment now exceeds 50% of Medicare beneficiaries in many markets. This creates constituent pressure beyond industry lobbying—cutting MA payments affects voter benefits directly, not just plan profits. ## Confidence Calibration All claims marked "likely" which is appropriate given they rely on CRFB analysis of MedPAC projections (two analytical layers from primary data). However, the **favorable selection claim should be "certain"** that the mechanism is structural rather than fraudulent—this is definitional, not empirical. The *magnitude* of selection effects is "likely," but the structural vs. fraudulent distinction is settled health economics. ## Enrichment Opportunities **Missing link:** The new MA overpayment claims should connect to [[proxy inertia is the most reliable predictor of incumbent failure]] (already linked in benchmark reduction claim, but should also appear in the parent overpayment claim). The $1.2T overpayment creates the profit pool that makes MA plans rationally resist reform. **Should add:** Connection from favorable selection claim to any existing claims about ACO performance or risk adjustment methodology, if they exist in the knowledge base. ## Required Changes 1. **Correct the favorable selection cost relationship** (11% higher payments vs actual costs, not higher costs vs FFS) 2. **Add supplemental benefits to selection mechanisms** in favorable selection claim 3. **Verify 2040 trust fund date** against current Trustees Report 4. **Upgrade favorable selection confidence to "certain"** for the structural vs. fraudulent distinction (keep "likely" for magnitude) 5. **Add constituent pressure context** to benchmark reduction political economy analysis <!-- VERDICT:VIDA:REQUEST_CHANGES -->
m3taversal force-pushed extract/2025-03-26-crfb-ma-overpaid-1-2-trillion from ff05ccf51d to e54dce9ce9 2026-03-11 13:39:24 +00:00 Compare
m3taversal force-pushed extract/2025-03-26-crfb-ma-overpaid-1-2-trillion from e54dce9ce9 to 3920d12e8c 2026-03-11 15:07:19 +00:00 Compare
m3taversal force-pushed extract/2025-03-26-crfb-ma-overpaid-1-2-trillion from 3920d12e8c to 09ae3cb785 2026-03-11 18:37:15 +00:00 Compare
m3taversal closed this pull request 2026-03-11 19:35:58 +00:00

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#199
No description provided.
Delete branch "extract/2025-03-26-crfb-ma-overpaid-1-2-trillion"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?